BioGaia appoints Theresa Agnew as new CEO

09-Aug-2023 - Sweden
Computer-generated image

Symbolic image

BioGaia´s board of directors has appointed Theresa P. Agnew as the new chief executive officer.

Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College.

At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide.

Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale.

"We are extremely pleased that we have been able to recruit Theresa Agnew”, says BioGaia’s founder and chair Peter Rothschild, and he continues: “She has successfully led OTC, diagnostics, and consumer health brands with a strong scientific basis and been a pioneer expanding distribution through internet platforms. She brings experience from turnaround environments as well as growth-oriented roles. Theresa has a deep knowledge of life science, as well as how to build and market strong and relevant consumer brands. Theresa will drive BioGaia to further accelerate its profitable growth journey and potential.”

"I am very excited about this opportunity and really look forward to contributing to an already successful business model and working with the talented global BioGaia team to grow BioGaia and create value for our consumers and shareholders”, says Theresa Agnew, future CEO of BioGaia.

Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

EVIDENT Corporation Appoints New CEO and COO

EVIDENT Corporation Appoints New CEO and COO

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

Biotage AB appointment of new CEO

Biotage AB appointment of new CEO

Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned

Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned

Beckman Coulter Life Sciences Names Joe Fox President

Beckman Coulter Life Sciences Names Joe Fox President

Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases

Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”